ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Clinical Utility of Treating Patients with Compounded “Bioidentical” Hormone Therapy (BHT).
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Dr Justin Saya MD" data-source="post: 161754" data-attributes="member: 12687"><p>They’re constantly trying to pinch the compounding pharmacies. As noted above, important distinction between 503a and 503b. The reputable 503b pharmacies (and most of their respective products) aren’t going anywhere, though they are under constant pressure from multiple angles (essential copy disputes, “do not compound” list modifications, big pharma intimidation tactics, etc). On a related note, the FDA recently placed GHRPs on the category 3 “do not compound” list. My team is sending out a notification this week regarding same. By the end of the year any compounding pharmacy still producing GHRP 2 and GHRP 6 will be in violation. Notably, this does NOT apply to ipamorelin or GHRH (sermorelin).</p></blockquote><p></p>
[QUOTE="Dr Justin Saya MD, post: 161754, member: 12687"] They’re constantly trying to pinch the compounding pharmacies. As noted above, important distinction between 503a and 503b. The reputable 503b pharmacies (and most of their respective products) aren’t going anywhere, though they are under constant pressure from multiple angles (essential copy disputes, “do not compound” list modifications, big pharma intimidation tactics, etc). On a related note, the FDA recently placed GHRPs on the category 3 “do not compound” list. My team is sending out a notification this week regarding same. By the end of the year any compounding pharmacy still producing GHRP 2 and GHRP 6 will be in violation. Notably, this does NOT apply to ipamorelin or GHRH (sermorelin). [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Clinical Utility of Treating Patients with Compounded “Bioidentical” Hormone Therapy (BHT).
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top